Department of Hematology and Oncology, The Affiliated Hospital of Jiujiang University, China
Research Article
Anlotinib Maintenance Following Adjuvant Chemotherapy in Newly Diagnosed Stage III-IV Patients with Epithelial Ovarian Cancer: A Retrospective Study
Author(s): Jianghua Ding*
Background and Aims: Anti-angiogenesis therapy with bevacizumab maintenance marginally improved the median
progression-free survival (mPFS) of 4.9 months in patients with advanced epithelial ovarian cancer (EOC). Anlotinib,
an oral small-molecular anti-angiogenic agent, has been reported to treat platinum-resistant EOC. However,
little is known about anlotinib maintenance therapy in newly diagnosed EOC.
Methods: This retrospective study included 20 patients with newly diagnosed EOC from a single hospital between
January 2020 and December 2021. The primary endpoints were mPFS, the overall response rate (ORR), and the
Disease Control Rate (DCR). Adverse reactions to therapy were also assessed.
Results: Among all EOC patients, the ORR was 65% (13/20) and the DCR was 95% (19/20), while the mPFS was
14.8 m.. View More»
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi 